EMA Authorised: Qalsody (tofersen) — Biogen Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Qalsody (tofersen) for amyotrophic lateral sclerosis, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Qalsody (Tofersen)

Snippet

Status: Authorised. Therapeutic area: Amyotrophic Lateral Sclerosis. MAH: Biogen Netherlands B.V.. Decision date: 09/07/2024. Orphan medicine